Last reviewed · How we verify
NCT07127094: BEGliTabATCO
Bioequivalence Assessment Between Two Imeglimin Hydrochloride Film Coated Tablet Formulations
Phase 1 trial testing Test Product (Glimcoza) in Bioequivalence Study in Healthy Subjects in 29 participants. Completed in 18 June 2025.
18 June 2025
Quick facts
| Lead sponsor | Aya Mohammed Abdel Magid Abdel Hamid |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 29 |
| Start date | 9 March 2025 |
| Primary completion | 18 June 2025 |
| Estimated completion | 18 June 2025 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- Test Product (Glimcoza) — full drug profile →
- Reference (R) Twymeeg® — full drug profile →
Conditions studied
- Bioequivalence Study in Healthy Subjects — all drugs for Bioequivalence Study in Healthy Subjects →
Sponsor
Aya Mohammed Abdel Magid Abdel Hamid — full company profile →
Who can join
Adults 18 to 55, any sex, with Bioequivalence Study in Healthy Subjects. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
An open label, randomized, single-dose, two-sequence, two-period, crossover study to assess the bioequivalence of Imeglimin HCl in Glimcoza 500 mg film coated tablet (Test product) in comparison with Twymeeg® 500 mg tablet (Reference product) in healthy 31 subjects under fasting condition.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07127094
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Aya Mohammed Abdel Magid Abdel Hamid trials
Trials by the same sponsor.
- NCT07121868 — Bioequivalence Assessment Between Two Cariprazine Hard Capsule Formulations · Phase 1 · completed
- NCT06969963 — Bioequivalence Assessment Between Two Perampanel Oral Suspension Formulations · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07127094 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Aya Mohammed Abdel Magid Abdel Hamid
- Last refreshed: 24 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07127094.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing